Form 8-K - Current report:
SEC Accession No. 0001193125-25-007383
Filing Date
2025-01-16
Accepted
2025-01-16 07:00:17
Documents
16
Period of Report
2025-01-13
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d891653d8k.htm   iXBRL 8-K 39550
2 EX-4.1 d891653dex41.htm EX-4.1 56520
3 EX-4.2 d891653dex42.htm EX-4.2 55678
4 EX-10.1 d891653dex101.htm EX-10.1 584349
  Complete submission text file 0001193125-25-007383.txt   1033405

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA anro-20250113.xsd EX-101.SCH 2877
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE anro-20250113_lab.xml EX-101.LAB 18737
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE anro-20250113_pre.xml EX-101.PRE 11725
18 EXTRACTED XBRL INSTANCE DOCUMENT d891653d8k_htm.xml XML 3770
Mailing Address 650 CASTRO STREET, SUITE 450 MOUNTAIN VIEW CA 94041
Business Address 650 CASTRO STREET, SUITE 450 MOUNTAIN VIEW CA 94041 773-255-5012
Alto Neuroscience, Inc. (Filer) CIK: 0001999480 (see all company filings)

EIN.: 834210124 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41944 | Film No.: 25534308
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)